Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations

Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations

Although small molecule tyrosine kinase inhibitors are effective in lung cancer driven by mutated EGFR, some receptor variants fail to respond. Here, the authors identify structural features of an important set of EGFR variants with reduced inhibitor sensitivity, guiding future inhibitor selection.

Bibliographic Details
Main Authors: Iris K. van Alderwerelt van Rosenburgh, David M. Lu, Michael J. Grant, Steven E. Stayrook, Manali Phadke, Zenta Walther, Sarah B. Goldberg, Katerina Politi, Mark A. Lemmon, Kumar D. Ashtekar, Yuko Tsutsui
Format: Article
Language:English
Published: Nature Portfolio 2022-11-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-022-34398-z

Internet

https://doi.org/10.1038/s41467-022-34398-z

Similar Items